Trial: Adjusting Atezolizumab Dose Based on Drug Levels in Blood
Treatments studied
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This study tests whether adjusting the dose of the immunotherapy drug atezolizumab (Tecentriq) based on its levels in your blood works well. You may be able to join if you have advanced cancer and your doctor already plans to give you this drug (alone or with other approved treatments).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have advanced or metastatic cancer that your doctor recommends treating with atezolizumab (brand name Tecentriq), either alone or with other approved drugs.
- Your tumor must be measurable on scans (like CT or MRI).
- You must be able to take care of yourself (up to some limitations; for example, you can be out of bed more than 50% of the time).
- Your liver, kidney, and blood counts must be within certain limits (a blood test will check this).
- If you are a woman who could become pregnant, you must use highly effective birth control during the study and for 5 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether atezolizumab combined with a multi-targeted (“multi-kinase”) inhibitor can treat advanced liver cancer that cannot be cured with surgery or local procedures. It focuses on people whose cancer has already grown despite a first-line treatment using atezolizumab plus bevacizumab.
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
This study tracks how well Atezolizumab (Tecentriq) works for people with certain lung or liver cancers in everyday medical practice. It helps doctors understand if patients are satisfied with their treatment and how it affects their quality of life.
This Phase 2 study tests atezolizumab, an immunotherapy drug, in people with advanced, incurable solid tumors whose tumor DNA/RNA suggests they may respond. The goal is to see if the treatment works better for patients selected by these lab results.
This trial tests a combination of two immunotherapy drugs (tiragolumab and atezolizumab) for people with advanced solid tumors that have stopped responding to standard treatments or cannot be treated with available therapies. It may be an option if your tumor has certain immune-related markers.
This trial tests if the immunotherapy drug atezolizumab can prevent early stage non-small cell lung cancer from coming back after surgery. It is for people whose tumors have high levels of a protein called PD-L1 (50% or more) and do not have certain gene changes (EGFR or ALK).
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.